About Partha Paliwal

This author has not yet filled in any details.
So far Partha Paliwal has created 13 blog entries.
16 03, 2023

Importance of matching the correct QP to your product

By |2023-03-16T13:55:56+00:00March 16th, 2023|Technical Article|

Introduction: MIA for Marketed Products: Importance of matching the correct QP to your product As science advances the types of products on offer have grown in complexity. From Oral Solid Dosage Forms  (OSD) to novel Cell and Gene Therapy products, the range of technical knowledge required is vast. At the very end of the manufacturing

13 03, 2023


By |2024-01-29T15:47:25+00:00March 13th, 2023|Events, General News|

MIAS Pharma will be attending 17th annual BIO-Europe Spring taking place March 20–22, 2023 in Basel, Switzerland. After being delivered digitally over the last two years, the event is expected to bring together over 2,800 executives from biotech, pharma and finance companies to engage in 15,000+ one-to-one meetings. BIO-Europe Spring is the place to meet

16 02, 2023

UK retains acceptance of batch testing and EU certification

By |2024-01-02T10:39:42+00:00February 16th, 2023|Featured, General News|

Last year, the UK Department of Health & Social Care issued a statement emphasizing their continued support for the acceptance of batch testing and certification by a Qualified Person (QP) performed in the EU. This statement came after a public consultation seeking opinions on four potential options for a batch testing policy in the UK

14 02, 2023

Q&As on GDP Requirements updated by the EMA

By |2024-01-23T15:49:36+00:00February 14th, 2023|General News|

The GMP/GDP Inspectors Working Group has put up and approved a list of frequently asked questions (FAQs) on Good manufacturing practice (GMP) and Good distribution practice (GDP) that the European Medicines Agency (EMA) posts on its website. The list was revised on January 2023. There were three more GDP-related questions added. Maintaining an eye on

7 02, 2023

QP Declaration for Investigational Medicinal Products

By |2024-03-26T09:50:07+00:00February 7th, 2023|Technical Article|

When submitting a trial application for a clinical trial in the EU/EEA using an Investigational Medicinal Product (IMP) manufactured in a 3rd country (a country not a member of the EU or EEA), a Qualified Person’s (QP) Declaration is required. This declaration is intended to guarantee that the IMP has been manufactured to standards at

3 02, 2023

Sponsor Responsibilities: IMP Shipping & Handling

By |2024-01-23T15:53:01+00:00February 3rd, 2023|General News|

In accordance with the "Guideline on the responsibilities of the sponsor with regard to handling and shipping of IMPs for human use in accordance with GCP and GMP," investigational medicinal products (IMPs) cannot be used in a clinical trial in a member state of the European Union until the two-step process has been completed. The

24 01, 2023

What should be taken into consideration when assessing suppliers?

By |2023-01-24T10:59:52+00:00January 24th, 2023|General News|

Wholesalers must ensure that their suppliers are permitted to supply pharmaceuticals. Legal History The following is applicable in accordance with chapter 5.2 of the EU GDP Guidelines (Guidelines on Good Distribution Practice of Medicinal Products for Human Use, 5 November 2013 - 2013/C 343/01): Only individuals who themselves have a wholesale distribution authorization or who

20 01, 2023

EMA starts a pilot study to analyze clinical trial raw data

By |2024-02-12T11:38:18+00:00January 20th, 2023|General News|

The European Medicines Agency (EMA) has launched a pilot project to assess the benefits of analyzing raw data from clinical trials by regulatory authorities when evaluating marketing authorization applications (MAAs) for new medicines, as well as post-authorization applications. Raw data constitutes individual patient data from clinical studies in electronic structured format that is directly accessible

13 01, 2023

Risks in global supply chains : Causes & Solutions

By |2023-01-13T15:21:52+00:00January 13th, 2023|General News|

The EU Commission has published a document on a "Structured Dialogue on the security of medicines supply". The document is based on a mandate for a dialogue of different actors in the value chain of medicines from manufacturing, authorities, non-governmental organisations as well as from research. The aim was to gain a better understanding of

Go to Top